SCHEMBL4028245

SCHEMBL4028245

CCC(C)OP(=O)(O)N1CCN(S(=O)(=O)c2ccccc2[N+](=O)[O-])CCCC(F)CCCN(S(=O)(=O)c2ccccc2[N+](=O)[O-])CC1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.51
ALDH1A1 P00352 4/20 0.48
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
HTT P42858 1/20 0.45
NPC1 O15118 1/20 0.45
MCOLN3 Q8TDD5 1/20 0.44
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
EPHX2 P34913 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032573 0.90 PKM (0.51) PKMALDH1A1KMT2AMEN1NPC1
SCHEMBL4028241 0.83 PKM (0.55) PKMALDH1A1KMT2AMEN1HTT
SCHEMBL4026842 0.74 ALDH1A1 (0.64) PKMALDH1A1KMT2AMEN1HTT
SCHEMBL3537955 0.73 ALDH1A1 (0.66) PKMALDH1A1KMT2AMEN1HTT
SCHEMBL4032571 0.72 PKM (0.55) PKMALDH1A1KMT2AMEN1MCOLN3
SCHEMBL5347059 0.69 ALDH1A1 (0.97) PKMALDH1A1KMT2AMEN1HTT
SCHEMBL2360974 0.69 ALDH1A1 (0.84) PKMALDH1A1KMT2AMEN1NPC1
SCHEMBL28137833 0.68 ALDH1A1 (1.00) PKMALDH1A1KMT2AMEN1HTT
SCHEMBL14256485 0.68 PKM (0.71) PKMALDH1A1KMT2AMEN1NPC1
SCHEMBL862065 0.67 PKM (0.74) PKMALDH1A1KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244648-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS GENZYME CORP (US) 2009-04-15 EP disclosed
US-20070060591-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2007-03-15 US disclosed
US-7022717-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2006-04-04 US disclosed
US-20060069129-A1 Chemokine receptor binding heterocyclic compounds BRIDGER GARY J 2006-03-30 US disclosed
US-20040102428-A1 Chemokine receptor binding heterocyclic compounds ANORMED CORPORATION (CA) 2004-05-27 US disclosed
US-6667320-B2 For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV) ANORMED (CA) 2003-12-23 US disclosed
US-20020077339-A1 Chemokine receptor binding heterocyclic compounds ANORMED CORPORATION (CA) 2002-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060591-A1 Chemokine receptor binding heterocyclic compounds CCR5, ACKR3, CCR2 PKM 1780/4885ALDH1A1 3141/4885KMT2A 2209/4885
US-20040102428-A1 Chemokine receptor binding heterocyclic compounds CCR5, ACKR3, CCR2 PKM 1780/4885ALDH1A1 3141/4885KMT2A 2209/4885
US-20020077339-A1 Chemokine receptor binding heterocyclic compounds CCR5, ACKR3, CCR2 PKM 1780/4885ALDH1A1 3141/4885KMT2A 2209/4885
US-20060069129-A1 Chemokine receptor binding heterocyclic compounds CCR5, ACKR3, CCR2 PKM 1780/4885ALDH1A1 3141/4885KMT2A 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.